Literature DB >> 947942

Effect of carbidopa on prolactin, growth hormone and cortisol secretion in man.

G M Brown, P E Garfinkel, J J Warsh, H C Stancer.   

Abstract

Serum prolactin, growth hormone and cortisol levels were examined in normal volunteers following administration of carbidopa, a peripheral decarboxylase inhibitor. 24-hour urinary tryptamine levels dropped markedly indicating that inhibition of decarboxylase was effective. Prolactin levels rose while growth hormone and cortisol remained unchanged. Since the tuberoinfundibular dopamine nerve terminals lie outside the blood brain barrier, this study suggests that these neurons are involved in prolactin but not in growth hormone or cortisol regulation. Findings are compatible with two alternate hypotheses--either that dopamine is a physiologic prolactin inhibiting factor (PIF) or that tuberoinfundibular dopamine neurons regulate the release of PIF.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 947942     DOI: 10.1210/jcem-43-1-236

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Dopamine during alpha- or beta-adrenergic blockade in man. Hormonal, metabolic, and cardiovascular effects.

Authors:  M Lorenzi; J H Karam; E Tsalikian; N V Bohannon; J E Gerich; P H Forsham
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

2.  Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.

Authors:  S A Fine; L A Frohman
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

3.  COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers.

Authors:  T Keränen; A Gordin; M Koulu; M Scheinin; S Antila; S Sundberg; T Wikberg
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.

Authors:  A Martinez-Campos; P Giovannini; E Parati; A Novelli; T Caraceni; E E Müller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-12       Impact factor: 10.154

Review 5.  Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications.

Authors:  E E Müller; V Locatelli; S Cella; A Peñalva; A Novelli; D Cocchi
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

6.  Abnormal regulation of prolactin release in idiopathic Parkinson's disease.

Authors:  N F Lawton; J MacDermot
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-11       Impact factor: 10.154

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.